Teriparatide, a recombinant fragment of the N-terminus of human PTH1-34, injected subcutaneously at daily intervals, will increase the number and activity of osteoblasts and is a synthetic agent of great value in the treatment of osteoporosis. It will significantly increase clinically relevant bone density, superior to the increase in vertebral and all trabecular bone positions by alun phosphate sodium. Teriparatide significantly reduces vertebral and non-vertebral fractures. This effect is maintained for several months after discontinuation of the drug, with a significant reduction in the relative risk for patients with a high risk of fracture. In addition this drug has been shown to be very effective in men with osteoporosis. Teriparatide is the first drug with an anti-fracture effect in the treatment of hormonal osteoporosis that significantly increases the BMD of the spine and hip compared to alun phosphate sodium. So far, anti-resorptive therapy such as bisphosphonates and raloxifene are the main drug treatment options for osteoporosis patients. With the application of teriparatide, the treatment of bone formation becomes possible. A large randomized double-blind study showed that subcutaneous application of 20ug per day significantly reduced vertebral fractures by 65% in female patients over 70 years of age. The incidence of moderate to severe or multiple fractures was reduced by 90% and 77%. There was also a 35% reduction in new non-vertebral fractures after 21 months of treatment. Recent studies have shown that teriparatide is best used as a monthly treatment and not in combination with bisphosphonates. Previous treatment with bisphosphonates may reduce the synthetic effect of teriparatide. In order to preserve bone volume after 18-24 recommended treatment cycles of teriparatide application, the application of the anti-resorptive drug alunphosphate can be followed.